The U.S. Food and Drug Administration (FDA) has requested that all manufacturers of sedative-hypnotic drug products, a class of drugs used to induce and/or maintain sleep,// strengthen their product labeling to include stronger language concerning potential risks. These risks include severe allergic reactions and complex sleep-related behaviors, which may include sleep-driving. Sleep driving is defined as driving while not fully awake after ingestion of a sedative-hypnotic product, with no memory of the event.

"There are a number of prescription sleep aids available that are well-tolerated and effective for many people," said Steven Galson, M.D., MPH, director of FDA’s Center for Drug Evaluation and Research. "However, after reviewing the available post-marketing adverse event information for these products, FDA concluded that labeling changes are necessary to inform health care providers and consumers about risks."

In December 2006, FDA sent letters to manufacturers of products approved for the treatment of sleep disorders requesting that the whole class of drugs revise product labeling to include warnings about the following potential adverse events:

· Anaphylaxis (severe allergic reaction) and angioedema (severe facial swelling), which can occur as early as the first time the product is taken.

· Complex sleep-related behaviors, which may include sleep-driving, making phone calls, and preparing and eating food (while asleep).

· FDA has been working with the product manufacturers over the past three months to update labeling, notify health care providers and inform consumers of these risks.

Along with the labeling revisions, FDA has requested that each product manufacturer send letters to health care providers to notify them about the new warnings. Manufacturers will begin sending these letters to providers starting this week.

In addition, FDA has requested that manufacturers of sedat
'"/>




Page: 1 2
Related medicine news :

1. Canadian Street Prostitutes Requests Protection
2. New Zealand Requests Details from Britain about ‘Black Sheep
3. Patients Requests for Antidepressants can Influence Physician Evaluation of Depression
4. Cyberkinetics Requests FDA to Sell Nerve Growth Stimulation System
5. GlaxoSmithKline - Changes Lamictal(R) Label Appearance and Packaging
6. Impotence Drugs Ordered by FDA to have Label Change
7. The Dangers Of Vitamin A To Pregnant Women To Be Included On Label
8. Identifying What Consumers Look For On Food Stuff Labels
9. Canada Introduces Mandatory Nutrition Labeling
10. Look For Food Allergens On The Product Label.
11. Nutritional Labels are the order of the day!